Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995315 · ClinicalTrials.gov registry record
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
A clinical trial, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- 13
- Enrollment target
NCT04995315: Completed study, sponsored by Agios Pharmaceuticals.
NCT04995315 is a clinical trial that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04995315 has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This is a substudy of Study AG348-C-008, an observational, longitudinal, multicenter, global registry that aims to better understand the longitudinal clinical implications of pyruvate kinase deficiency (PK deficiency). The primary purpose of this study is to describe the cognition of participants with PK deficiency, as objectively measured by the Cogstate Brief Battery (CBB).
Primary Outcome
CBB is a series of brief computerized assessments used to evaluate 4 major cognitive domains: psychomotor speed, attention/vigilance, visual learning, and working memory. If the CBB score falls between -10 to +10, it is considered normal. In Cogstate scoring 0 could be considered as performing in the average range, a negative score means below-average performance, and a positive score means above-average performance. A positive change in scores indicates slightly better performance.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2023-09-22 |
What the finished NCT04995315 record still lists
NCT04995315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04995315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04995315 about?
NCT04995315 is a clinical study titled "Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008". This is a substudy of Study AG348-C-008, an observational, longitudinal, multicenter, global registry that aims to better understand the longitudinal clinical implications of pyruvate kinase deficiency (PK deficiency). The primary purpose of this study is to describe the cognition of participants wi...
What is the current status of trial NCT04995315?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2021-07-02. Estimated completion is 2023-09-22.
Who is sponsoring clinical trial NCT04995315?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI